Research & Literature

Pituitary-Targeted Dynamic Contrast-Enhanced Multisection CT for Detecting MR Imaging-Occult Functional Pituitary Microadenoma.

Kinoshita M, Tanaka H, Arita H, et al.

AJNR. American journal of neuroradiology 2015; (36(5)):904-8 doi:10.3174/ajnr.A4220.

Bone and Joint Disorders in Acromegaly.

Claessen KM, Mazziotti G, Biermasz NR, Giustina A

Neuroendocrinology 2016; (103(1)):86-95 doi:10.1159/000375450.

The influence of pituitary adenoma size on vision and visual outcomes after trans-sphenoidal adenectomy: a report of 78 cases.

Ho RW, Huang HM, Ho JT

Journal of Korean Neurosurgical Society 2015; (57(1)):23-31 doi:10.3340/jkns.2015.57.1.23.

X-linked acrogigantism syndrome: clinical profile and therapeutic responses.

Beckers A, Lodish MB, Trivellin G, et al.

Endocrine-related cancer 2015; (22(3)):353-67 doi:10.1530/ERC-15-0038.

Pasireotide in Acromegaly: An Overview of Current Mechanistic and Clinical Data.

Samson SL

Neuroendocrinology 2015; (102(1-2)):8-17 doi:10.1159/000381460.

Acromegaly: otolaryngic manifestations following pituitary surgery.

Kuan EC, Peng KA, Kita AE, et al.

American journal of otolaryngology 2015; (36(4)):521-5.

Clinical and genetic characterization of pituitary gigantism: an international collaborative study in 208 patients.

Rostomyan L, Daly AF, Petrossians P, et al.

Endocrine-related cancer 2015; (22(5)):745-57 doi:10.1530/ERC-15-0320.

Cardiovascular Disease and Sleep-Disordered Breathing in Acromegaly.

Powlson AS, Gurnell M

Neuroendocrinology 2016; (103(1)):75-85 doi:10.1159/000438903.

Reversible Growth Hormone Excess in Two Girls with Neurofibromatosis Type 1 and Optic Pathway Glioma.

Bruzzi P, Sani I, Albanese A

Hormone research in paediatrics 2015; (84(6)):414-22 doi:10.1159/000440956.

Somatic mosaicism underlies X-linked acrogigantism syndrome in sporadic male subjects.

Daly AF, Yuan B, Fina F, et al.

Endocrine-related cancer 2016; (23(4)):221-33 doi:10.1530/ERC-16-0082.

Somatic GPR101 Duplication Causing X-Linked Acrogigantism (XLAG)-Diagnosis and Management.

Rodd C, Millette M, Iacovazzo D, et al.

The Journal of clinical endocrinology and metabolism 2016; (101(5)):1927-30 doi:10.1210/jc.2015-4366.

Germline or somatic GPR101 duplication leads to X-linked acrogigantism: a clinico-pathological and genetic study.

Iacovazzo D, Caswell R, Bunce B, et al.

Acta neuropathologica communications 2016; (4(1)):56 doi:10.1186/s40478-016-0328-1.

Combined treatment with octreotide LAR and pegvisomant in patients with pituitary gigantism: clinical evaluation and genetic screening.

Mangupli R, Rostomyan L, Castermans E, et al.

Pituitary 2016; (19(5)):507-14 doi:10.1007/s11102-016-0732-3.

Pegvisomant: a growth hormone receptor antagonist used in the treatment of acromegaly.

Tritos NA, Biller BM

Pituitary 2017; (20(1)):129-135 doi:10.1007/s11102-016-0753-y.

Genetics of gigantism and acromegaly.

Hannah-Shmouni F, Trivellin G, Stratakis CA

Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society 2016; (30-31()):37-41 doi:10.1016/j.ghir.2016.08.002.

Novel Genetic Causes of Pituitary Adenomas.

Caimari F, Korbonits M

Clinical cancer research : an official journal of the American Association for Cancer Research 2016; (22(20)):5030-5042 doi:10.1158/1078-0432.CCR-16-0452.

Acromegaly: clinical features at diagnosis.

Vilar L, Vilar CF, Lyra R, et al.

Pituitary 2017; (20(1)):22-32 doi:10.1007/s11102-016-0772-8.

Somatostatin and dopamine receptor regulation of pituitary somatotroph adenomas.

Ben-Shlomo A, Liu NA, Melmed S

Pituitary 2017; (20(1)):93-99 doi:10.1007/s11102-016-0778-2.

Complications of acromegaly: cardiovascular, respiratory and metabolic comorbidities.

Pivonello R, Auriemma RS, Grasso LF, et al.

Pituitary 2017; (20(1)):46-62 doi:10.1007/s11102-017-0797-7.

Airway and sleep disorders in patients with acromegaly.

Turan O, Akinci B, Ikiz AO, et al.

The clinical respiratory journal 2018; (12(3)):1003-1010 doi:10.1111/crj.12618.

Efficacy of transsphenoidal surgery in achieving biochemical cure of growth hormone-secreting pituitary adenomas among patients with cavernous sinus invasion: a systematic review and meta-analysis.

Briceno V, Zaidi HA, Doucette JA, et al.

Neurological research 2017; (39(5)):387-398 doi:10.1080/01616412.2017.1296653.

Progression from isolated growth hormone deficiency to combined pituitary hormone deficiency.

Cerbone M, Dattani MT

Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society 2017; (37()):19-25 doi:10.1016/j.ghir.2017.10.005.

Clinical characteristics and ophthalmologic findings of pituitary adenoma in Korean patients.

Kim TG, Jin KH, Kang J

International ophthalmology 2019; (39(1)):21-31 doi:10.1007/s10792-017-0778-x.

Turner Syndrome: transition from childhood to adolescence.

Kosteria I, Kanaka-Gantenbein C

Metabolism: clinical and experimental 2018; (86()):145-153 doi:10.1016/j.metabol.2017.12.016.

Pediatric Pituitary Adenoma: Case Series, Review of the Literature, and a Skull Base Treatment Paradigm.

Perry A, Graffeo CS, Marcellino C, et al.

Journal of neurological surgery. Part B, Skull base 2018; (79(1)):91-114 doi:10.1055/s-0038-1625984.

Risk category system to identify pituitary adenoma patients with AIP mutations.

Caimari F, Hernández-Ramírez LC, Dang MN, et al.

Journal of medical genetics 2018; (55(4)):254-260 doi:10.1136/jmedgenet-2017-104957.

Pediatric Pituitary Adenomas: Early and Long-Term Surgical Outcome in a Series of 85 Consecutive Patients.

Barzaghi LR, Losa M, Capitanio JF, et al.

Neurosurgery 2019; (85(1)):65-74 doi:10.1093/neuros/nyy204.

The relation of pituitary adenomas invasiveness and the proliferative index measured by immunoexpression of topoisomerase IIα.

Kwinta BM, Wilk A, Trofimiuk-Muldner M, et al.

Endokrynologia Polska 2018; (69(5)):530-535 doi:10.5603/EP.a2018.0050.

Inoperable Giant Growth Hormone-secreting Pituitary Adenoma: Radiological Aspects, Clinical Management and Pregnancy Outcome.

Dicuonzo F, Purciariello S, De Marco A, et al.

Endocrine, metabolic & immune disorders drug targets 2019; (19(2)):214-220 doi:10.2174/1871530318666180807160712.

Gigantism in a McCune-Albright's syndrome with calcified GH-releasing pituitary adenoma: Case report and literature review.

Vega-Arroyo M, Tena-Suck ML, Álvarez-Gamiño CTJ, et al.

International journal of surgery case reports 2018; (53()):61-65 doi:10.1016/j.ijscr.2018.10.030.

Is GH nadir during OGTT a reliable test for diagnosis of acromegaly in patients with abnormal glucose metabolism?

Dobri G, Niwattisaiwong S, Bena JF, et al.

Endocrine 2019; (64(1)):139-146 doi:10.1007/s12020-018-1805-z.

Carney Complex.

Kamilaris CDC, Faucz FR, Voutetakis A, Stratakis CA

Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association 2019; (127(2-03)):156-164 doi:10.1055/a-0753-4943.

Growth Hormone Response to Oral Glucose Load: From Normal to Pathological Conditions.

Hage M, Kamenický P, Chanson P

Neuroendocrinology 2019; (108(3)):244-255 doi:10.1159/000497214.

Outcomes After Gamma Knife Stereotactic Radiosurgery in Pediatric Patients with Cushing Disease or Acromegaly: A Multi-Institutional Study.

Shrivastava A, Mohammed N, Xu Z, et al.

World neurosurgery 2019; (125()):e1104-e1113 doi:10.1016/j.wneu.2019.01.252.

AIP-mutated acromegaly resistant to first-generation somatostatin analogs: long-term control with pasireotide LAR in two patients.

Daly AF, Rostomyan L, Betea D, et al.

Endocrine connections 2019; (8(4)):367-377.

Pituitary gigantism: a rare learning opportunity.

Bendor-Samuel OM, Pal A, Cudlip S, et al.

Archives of disease in childhood. Education and practice edition 2020; (105(2)):111-116 doi:10.1136/archdischild-2018-316282.

Pituitary gigantism: a case series from Hospital de San José (Bogotá, Colombia).

García WR, Cortes HT, Romero AF

Archives of endocrinology and metabolism 2019; (63(4)):385-393 doi:10.20945/2359-3997000000150.

Insulin Resistance in Patients With Acromegaly.

Vila G, Jørgensen JOL, Luger A, Stalla GK

Frontiers in endocrinology 2019; (10()):509 doi:10.3389/fendo.2019.00509.

Mixed gangliocytoma-pituitary adenoma containing GH and GHRH co-secreting adenoma cells.

Teramoto S, Tange Y, Ishii H, et al.

Endocrinology, diabetes & metabolism case reports 2019; (2019()).

Diagnosis, treatment and follow-up of patients with acromegaly in a clinical practice setting in Spain: the ACROPRAXIS program Delphi survey.

de Pablos-Velasco P, Venegas EM, Álvarez Escolá C, et al.

Pituitary 2020; (23(2)):129-139 doi:10.1007/s11102-019-01012-3.

McCune-Albright syndrome and type 1 diabetes mellitus: a novel presentation.

Chatty P, Khattab A, Marshall I

Annals of the New York Academy of Sciences 2020; (1463(1)):5-8 doi:10.1111/nyas.14310.

HEREDITARY ENDOCRINE TUMOURS: CURRENT STATE-OF-THE-ART AND RESEARCH OPPORTUNITIES: The roles of AIP and GPR101 in familial isolated pituitary adenomas (FIPA).

Vasilev V, Daly AF, Trivellin G, et al.

Endocrine-related cancer 2020; (27(8)):T77-T86.

Acromegaly, inflammation and cardiovascular disease: a review.

Wolters TLC, Netea MG, Riksen NP, et al.

Reviews in endocrine & metabolic disorders 2020; (21(4)):547-568 doi:10.1007/s11154-020-09560-x.

Modern Radiotherapy for Pediatric Brain Tumors.

DeNunzio NJ, Yock TI

Cancers 2020; (12(6)) doi:10.3390/cancers12061533.

Pituitary Disease in AIP Mutation-Positive Familial Isolated Pituitary Adenoma (FIPA): A Kindred-Based Overview.

Bilbao Garay I, Daly AF, Egaña Zunzunegi N, Beckers A

Journal of clinical medicine 2020; (9(6)) doi:10.3390/jcm9062003.

Combined therapy of somatostatin analogues with pegvisomant for the treatment of acromegaly: a meta-analysis of prospective studies.

Ma L, Luo D, Yang T, et al.

BMC endocrine disorders 2020; (20(1)):126 doi:10.1186/s12902-020-0545-2.

A Chinese Case of X-Linked Acrogigantism and Systematic Review.

Liang H, Gong F, Liu Z, et al.

Neuroendocrinology 2021; (111(12)):1164-1175 doi:10.1159/000512240.

Evolving pituitary hormone deficits in primarily isolated GHD: a review and experts' consensus.

Binder G, Schnabel D, Reinehr T, et al.

Molecular and cellular pediatrics 2020; (7(1)):16 doi:10.1186/s40348-020-00108-2.

Rapid progression of scoliosis curve in a mature patient with undiagnosed pituitary macroadenoma: A rare case report.

Chung WH, Chiu CK, Wei Chan CY, Kwan MK

Acta orthopaedica et traumatologica turcica 2020; (54(5)):561-564 doi:10.5152/j.aott.2020.19144.

Prognostic Factors of Acromegalic Patients with Growth Hormone-Secreting Pituitary Adenoma After Transsphenoidal Surgery.

Taweesomboonyat C, Oearsakul T

World neurosurgery 2021; (146()):e1360-e1366 doi:10.1016/j.wneu.2020.12.013.

Genetics of Acromegaly and Gigantism.

Bogusławska A, Korbonits M

Journal of clinical medicine 2021; (10(7)) doi:10.3390/jcm10071377.

An Update on Pituitary Neuroendocrine Tumors Leading to Acromegaly and Gigantism.

Asa SL, Ezzat S

Journal of clinical medicine 2021; (10(11)) doi:10.3390/jcm10112254.

Treatment of acromegaly by rosiglitazone via upregulating 15-PGDH in both pituitary adenoma and liver.

Zhang Y, Wang M, Ji C, et al.

iScience 2021; (24(9)):102983 doi:10.1016/j.isci.2021.102983.

Successful treatment of pituitary gigantism.

Cunha C, Saraiva C, Canas Marques C, Duarte JS

BMJ case reports 2021; (14(12)) doi:10.1136/bcr-2021-247989.

Towards a pituitary apoplexy classification based on clinical presentation and patient journey.

Guijt MC, Zamanipoor Najafabadi AH, Notting IC, et al.

Endocrine 2022; (76(1)):132-141 doi:10.1007/s12020-022-02983-3.

Duplications disrupt chromatin architecture and rewire GPR101-enhancer communication in X-linked acrogigantism.

Franke M, Daly AF, Palmeira L, et al.

American journal of human genetics 2022; (109(4)):553-570 doi:10.1016/j.ajhg.2022.02.002.

Pediatric Continuous Reference Intervals of Serum Insulin-like Growth Factor 1 Levels in a Healthy Chinese Children Population - Based on PRINCE Study.

Cao B, Peng Y, Song W, et al.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 2022; (28(7)):696-702 doi:10.1016/j.eprac.2022.04.004.

Complicated Clinical Course in Incipient Gigantism Due to Treatment-resistant Aryl Hydrocarbon Receptor-Interacting Protein-mutated Pediatric Somatotropinoma.

van Santen SS, Daly AF, Buchfelder M, et al.

AACE clinical case reports 2022; (8(3)):119-123 doi:10.1016/j.aace.2021.12.003.

The Spectrum of Familial Pituitary Neuroendocrine Tumors.

Armeni E, Grossman A

Endocrine pathology 2023; (34(1)):57-78 doi:10.1007/s12022-022-09742-0.

Two Unusual Cases of Pituitary Tumors Presenting with Pediatric Acromegaly.

Gurnurkar S, Patel U, Seekford J, et al.

Cureus 2022; (14(11)):e31604 doi:10.7759/cureus.31604.

Approach to the Patient: A Case With an Unusual Cause of Hypopituitarism.

Das L, Dutta P

The Journal of clinical endocrinology and metabolism 2023; (108(6)):1488-1504 doi:10.1210/clinem/dgac747.

Challenges in the Management of a 7-Year-Old Child with Thyrotropin-Secreting Pituitary Adenoma and the Review of the Literature.

Kirkgoz T, Abali S, Seker A, et al.

Hormone research in paediatrics 2023; (96(5)):527-537 doi:10.1159/000529070.

Pituitary Apoplexy Secondary to Thrombocytopenia due to Severe Acute Respiratory Syndrome Coronavirus 2 Infection: Report of a Rare Case and Literature Review.

Aghdam KA, Abtahi ZA, Sonbolestan SA, Sanjari MS

Journal of current ophthalmology 2022; (34(3)):364-368 doi:10.4103/joco.joco_321_21.

Outcomes of Endoscopic Transsphenoidal Approach for More Aggressive Pediatric Pituitary Adenomas: Early- and Late-Term Results from a Single Center Experience.

Caklili M, Yilmaz E, Duman Ozturk S, et al.

World neurosurgery 2023; (176()):e623-e633 doi:10.1016/j.wneu.2023.05.111.

Pituitary function at presentation and following therapy in patients with non-functional pituitary macroadenomas: a single centre retrospective cohort study.

Hussein Z, Marcus HJ, Grieve J, et al.

Endocrine 2023; (82(1)):143-151 doi:10.1007/s12020-023-03434-3.

[Secondary tumors following radiation therapy and chemotherapy : Incidence of cavernous hemangiomas].

Reith W, Yilmaz U

Radiologie (Heidelberg, Germany) 2023; (63(8)):603-608 doi:10.1007/s00117-023-01170-3.

Acromegaly with initial negative oral glucose tolerance test: a case report.

Tsai WH, Chien MN, Dai SH, Chan YK

Journal of medical case reports 2023; (17(1)):333 doi:10.1186/s13256-023-04064-z.

Tall stature and gigantism in transition age: clinical and genetic aspects-a literature review and recommendations.

Sada V, Puliani G, Feola T, et al.

Journal of endocrinological investigation 2024; (47(4)):777-793 doi:10.1007/s40618-023-02223-z.

Consensus on criteria for acromegaly diagnosis and remission.

Giustina A, Biermasz N, Casanueva FF, et al.

Pituitary 2024; (27(1)):7-22 doi:10.1007/s11102-023-01360-1.

Consensus guideline for the diagnosis and management of pituitary adenomas in childhood and adolescence: Part 2, specific diseases.

Korbonits M, Blair JC, Boguslawska A, et al.

Nature reviews. Endocrinology 2024; (20(5)):290-309 doi:10.1038/s41574-023-00949-7.

Management of pasireotide-induced hyperglycemia in patients with acromegaly: An experts' consensus statement.

Störmann S, Meyhöfer SM, Groener JB, et al.

Frontiers in endocrinology 2024; (15()):1348990 doi:10.3389/fendo.2024.1348990.

Predictive factors for radiation-induced pituitary damage in pediatric patients with brain tumors.

Gorenstein L, Shrot S, Ben-Ami M, et al.

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 2024; (196()):110268 doi:10.1016/j.radonc.2024.110268.

Pituitary Apoplexy: An Updated Review.

Iglesias P

Journal of clinical medicine 2024; (13(9)) doi:10.3390/jcm13092508.

Germline AIP variants in sporadic young acromegaly and pituitary gigantism: clinical and genetic insights from a Han Chinese cohort.

Xiang B, Zhang X, Liu W, et al.

Endocrine 2024; (85(3)):1346-1356 doi:10.1007/s12020-024-03898-x.

Growth hormone receptor antagonist pegvisomant and its role in the medical therapy of growth hormone excess.

MacFarlane J, Korbonits M

Best practice & research. Clinical endocrinology & metabolism 2024; (38(4)):101910 doi:10.1016/j.beem.2024.101910.

Diagnostic, therapeutic, and prognostic characteristics of patients with acromegaly according to tumor size at diagnosis.

Del Corso LM, Mesa Junior CO, Andrade VFC, et al.

Pituitary 2024; (27(5)):537-544 doi:10.1007/s11102-024-01432-w.

Spontaneous Cushing's Disease Remission Induced by Pituitary Apoplexy.

Esquivel JE, Santos AB, Hong A, Ruiz F

Cureus 2024; (16(7)):e64231 doi:10.7759/cureus.64231.

Transnasal Transsphenoidal Approach for a Nine-Year-Old Child With Pituitary Apoplexy: A Case Report.

Al-Juboori AA, Badran SA, Shahadha AA, et al.

Cureus 2024; (16(7)):e64525 doi:10.7759/cureus.64525.

Distinct clinical characteristics and prognosis of pediatric-onset growth hormone-secreting pituitary adenoma (GHPA) patients compared to adult-onset patients.

Zheng XQ, Yang SM, Xiao TX, et al.

Endocrine 2025; (87(1)):295-303 doi:10.1007/s12020-024-04044-3.

Diagnosis and management of pituitary adenomas in children and adolescents.

Maiter D, Chanson P, Constantinescu SM, Linglart A

European journal of endocrinology 2024; (191(4)):R55-R69 doi:10.1093/ejendo/lvae120.

Establishment of IGF-1 and IGFBP-3 continuous reference percentiles from data of healthy children using three kinds of immunoassay systems.

Jo Y, Song K, Heo SJ, et al.

Heliyon 2024; (10(19)):e38245 doi:10.1016/j.heliyon.2024.e38245.

Pituitary Gigantism in an Adolescent Girl With Postsurgical Residual Disease Treated With Lanreotide.

Kanley AM, Bossert WL, Elrokhsi SH

JCEM case reports 2025; (3(1)):luae225 doi:10.1210/jcemcr/luae225.

Growth hormone signaling and clinical implications: from molecular to therapeutic perspectives.

Aghili ZS, Khoshnevisan G, Mostoli R, et al.

Molecular biology reports 2025; (52(1)):202 doi:10.1007/s11033-025-10304-w.

Safe Continuation of Pegvisomant During Pregnancy in a Patient With Fibrous Dysplasia/McCune-Albright Syndrome.

Tan JY, Chemmanam J, Burt MG, et al.

JCEM case reports 2025; (3(6)):luaf095 doi:10.1210/jcemcr/luaf095.

A Pituitary Macroadenoma Cosecreting Prolactin and Growth Hormone in a Patient With Multiple Endocrine Neoplasia Type 4.

Green L, Simpson M, Bahri A, et al.

JCEM case reports 2025; (3(7)):luaf124 doi:10.1210/jcemcr/luaf124.

Mammosomatotroph pituitary neuroendocrine tumour in a 7-year-old boy: case report.

Lin W, Qiu Y, Ma Z, et al.

Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery 2026; (42(1)).

AIP expression and imaging findings in somatotroph adenomas after pre-operative lanreotide therapy for acromegaly.

Edlmann E, Shahzad M, Yuen J, et al.

Pituitary 2026; (29(2)).

Genome architecture in endocrine diseases: X-linked acrogigantism (X-LAG) syndrome.

Daly AF, Beckers A, Pétrossians P

Annales d'endocrinologie 2026; (87(2)):102511 doi:10.1016/j.ando.2026.102511.

Skin lesions in patients treated with growth hormone and those with growth hormone excess: a current overview.

Matwiejuk M, Myśliwiec H, Miklosz A, et al.

Frontiers in medicine 2026; (13()):1777658 doi:10.3389/fmed.2026.1777658.

Acromegaly and clinical manifestations.

Villar-Taibo R, Fernández-Rodríguez E, Bernabéu I

Vitamins and hormones 2026; (131()):153-193 doi:10.1016/bs.vh.2025.10.004.

Gigantism.

Donato S, Regala C, Marques P

Vitamins and hormones 2026; (131()):195-234 doi:10.1016/bs.vh.2025.10.005.

Genetics of familial acromegaly and pituitary gigantism.

De Sousa SMC, Daly AF

The Journal of clinical endocrinology and metabolism 2026; (111(Supplement_1)):S13-S26 doi:10.1210/clinem/dgag151.

Long-term safety and efficacy of pegvisomant monotherapy for acromegaly: final data from the full ACROSTUDY cohort.

Yuen KCJ, Vila G, Bernabeu I, et al.

Pituitary 2026; (29(3)).

GHRH and insulin hypersecretion from a pancreatic neuroendocrine tumor in multiple endocrine neoplasia type 1.

Lamback E, Bulzico DA, Lourenço DM, et al.

JCEM case reports 2026; (4(4)):luag002 doi:10.1210/jcemcr/luag002.

Genome architecture in endocrine diseases: X-Linked Acrogigantism (X-LAG) syndrome.

Daly AF, Beckers A, Pétrossians P

Annales d'endocrinologie 2026; (87(3)):102554 doi:10.1016/j.ando.2026.102554.

Cushing's syndrome and early growth hormone hypersecretion in a child with Carney complex: a case report.

Pietropaolo G, Festa A, Rivetti G, et al.

Frontiers in endocrinology 2026; (17()):1843310 doi:10.3389/fendo.2026.1843310.

Higher surgical cure of pediatric gigantism with endoscopic endonasal surgery: case series and review of the literature.

Garton ALA, Guadix SW, Vuguin PM, et al.

Pituitary 2026; (29(4)).

Postoperative Pituitary MRI Findings in Acromegaly: A Pictorial Review.

Daskareh M, Abbasi F, Emamzadeh N, et al.

Diagnostics (Basel, Switzerland) 2026; (16(16)) doi:10.3390/diagnostics16162582.